Search - tctmd.com

Displaying 21 - 40 of 170

Sort: Relevancy | Date

News Daily News

Mayor Riesgo de Trombsosis del Dispositivo con Andamiajes Bioabsorbibles Aunque Algunos Riesgos Pueden Mitigarse

Michael O'Riordan

February 23, 2016

News Daily News

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

Michael O'Riordan

February 23, 2016

News Daily News

SORT OUT IV at 5 Years: Better Long-term Safety Confirmed for Second Generation Stents

L.A. McKeown

February 16, 2016

News Daily News

5 年时 SORT OUT IV：已证实第二代支架的长期安全性更佳

L.A. McKeown

February 16, 2016

Presentation

Safety and Efficacy of EES vs SES: 5-Year Results from SORT OUT IV

Presenter: Okkels Jensen

February 15, 2016

News Daily News

糖尿病对 DES 治疗的患者的影响甚于病变复杂性

L.A. McKeown

February 03, 2016

News Daily News

La Diabetes Influye Más que la Complejidad de la Enfermedad en Pacientes Tratados con SLF

L.A. McKeown

February 03, 2016

News Daily News

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

L.A. McKeown

February 03, 2016

News Conference News TCT 2015

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Daily News

OPTIMAX: Prometedores Primeros Resultados en Humanos de un Stent Biocompatible de Cobalto-Cromo

Yael L. Maxwell

September 14, 2015

News Daily News

OPTIMAX: First-in-Human Results Promising for Biocompatible Cobalt-Chromium Stent

Yael L. Maxwell

September 14, 2015

News Daily News

OPTIMAX：生物相容性钴铬支架的首例人类结果前景看好

Yael L. Maxwell

September 14, 2015

News Conference News ESC 2015

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Caitlin E. Cox

September 02, 2015

News Conference News ESC 2015

ABSORB Trials Pit BRS Against Second-Generation DES

Caitlin E. Cox

September 02, 2015

News Daily News

登记研究表明 Absorb BVS 治疗所有糖尿病患者的效果与 DES 相当

August 27, 2015

Advertisement

Mayor Riesgo de Trombsosis del Dispositivo con Andamiajes Bioabsorbibles Aunque Algunos Riesgos Pueden Mitigarse

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

SORT OUT IV at 5 Years: Better Long-term Safety Confirmed for Second Generation Stents

5 年时 SORT OUT IV：已证实第二代支架的长期安全性更佳

Safety and Efficacy of EES vs SES: 5-Year Results from SORT OUT IV

糖尿病对 DES 治疗的患者的影响甚于病变复杂性

La Diabetes Influye Más que la Complejidad de la Enfermedad en Pacientes Tratados con SLF

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

OPTIMAX: Prometedores Primeros Resultados en Humanos de un Stent Biocompatible de Cobalto-Cromo

OPTIMAX: First-in-Human Results Promising for Biocompatible Cobalt-Chromium Stent

OPTIMAX：生物相容性钴铬支架的首例人类结果前景看好

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

ABSORB Trials Pit BRS Against Second-Generation DES

登记研究表明 Absorb BVS 治疗所有糖尿病患者的效果与 DES 相当

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content